Dupont Capital Management Corp cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 158,184 shares of the biopharmaceutical company’s stock after selling 6,182 shares during the quarter. Dupont Capital Management Corp’s holdings in Bristol-Myers Squibb were worth $9,820,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 7.2% during the 2nd quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock worth $6,193,296,000 after buying an additional 7,517,623 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Bristol-Myers Squibb by 44.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock worth $587,287,000 after buying an additional 2,903,920 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Bristol-Myers Squibb by 114.5% during the 2nd quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock worth $383,119,000 after buying an additional 3,695,485 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Bristol-Myers Squibb by 2.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 6,283,205 shares of the biopharmaceutical company’s stock worth $347,713,000 after buying an additional 172,417 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in Bristol-Myers Squibb by 13.9% during the 3rd quarter. Bank of Montreal Can now owns 5,862,162 shares of the biopharmaceutical company’s stock worth $363,924,000 after buying an additional 717,503 shares in the last quarter. Institutional investors own 72.54% of the company’s stock.
Shares of BMY opened at $53.39 on Friday. Bristol-Myers Squibb Co has a twelve month low of $46.94 and a twelve month high of $70.05. The firm has a market capitalization of $86.49 billion, a PE ratio of 17.74, a PEG ratio of 1.48 and a beta of 1.08. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. Equities analysts expect that Bristol-Myers Squibb Co will post 3.88 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
A number of research firms have issued reports on BMY. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, July 15th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price objective on the stock in a report on Wednesday, August 8th. Barclays raised their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Finally, Credit Suisse Group restated a “hold” rating and issued a $61.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $62.48.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Reverse Stock Split
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.